| Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial JF Howard, V Bril, T Vu, C Karam, S Peric, T Margania, H Murai, ... The Lancet Neurology 20 (7), 526-536, 2021 | 440 | 2021 |
| Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study L Wieske, KPJ van Dam, M Steenhuis, EW Stalman, LYL Kummer, ... The Lancet Rheumatology 4 (5), e338-e350, 2022 | 123 | 2022 |
| Fatigue in patients with myasthenia gravis. A systematic review of the literature AM Ruiter, JJGM Verschuuren, MR Tannemaat Neuromuscular Disorders 30 (8), 631-639, 2020 | 72 | 2020 |
| Pedunculopontine cholinergic cell loss in hallucinating Parkinson disease patients but not in dementia with Lewy bodies patients DH Hepp, AM Ruiter, Y Galis, P Voorn, AJM Rozemuller, HW Berendse, ... Journal of neuropathology and experimental neurology 72 (12), 1162-1170, 2013 | 60 | 2013 |
| Breakthrough SARS-CoV-2 infections with the delta (B. 1.617. 2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy … L Boekel, EW Stalman, L Wieske, F Hooijberg, KPJ van Dam, YR Besten, ... The Lancet Rheumatology 4 (6), e417-e429, 2022 | 59 | 2022 |
| Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases L Wieske, LYL Kummer, KPJ van Dam, EW Stalman, AJ van der Kooi, ... BMC medicine 20 (1), 100, 2022 | 28 | 2022 |
| Prevalence and associated factors of fatigue in autoimmune myasthenia gravis AM Ruiter, JJGM Verschuuren, MR Tannemaat Neuromuscular Disorders 31 (7), 612-621, 2021 | 27 | 2021 |
| Idiopathic granulomatous mastitis: a great imitator? AM Ruiter, IL Vegting, PWB Nanayakkara Case Reports 2010, bcr0320102844, 2010 | 22 | 2010 |
| Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations KPJ van Dam, L Wieske, EW Stalman, LYL Kummer, J Roosen, ... Journal of autoimmunity 135, 102984, 2023 | 19 | 2023 |
| Breakthrough infections with the SARS-CoV-2 omicron (B. 1.1. 529) variant in patients with immune-mediated inflammatory diseases EW Stalman, L Wieske, KPJ van Dam, LY Kummer, ZLE van Kempen, ... Annals of the Rheumatic Diseases 81 (12), 1757-1766, 2022 | 18 | 2022 |
| Accuracy of patient-reported data for an online patient registry of autoimmune myasthenia gravis and Lambert-Eaton myasthenic syndrome AM Ruiter, E Strijbos, RHP de Meel, AF Lipka, WF Raadsheer, ... Neuromuscular Disorders 31 (7), 622-632, 2021 | 15 | 2021 |
| Assessing facial weakness in myasthenia gravis with facial recognition software and deep learning AM Ruiter, Z Wang, Z Yin, WC Naber, J Simons, JT Blom, JC van Gemert, ... Annals of clinical and translational neurology 10 (8), 1314-1325, 2023 | 12 | 2023 |
| Enrichment of serum IgG4 in MuSK myasthenia gravis patients DLE Vergoossen, AM Ruiter, KR Keene, EH Niks, MR Tannemaat, ... Journal of Neuroimmunology 373, 577978, 2022 | 9 | 2022 |
| T2B! Immunity against SARS-CoV-2 study group. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on … L Wieske, KPJ van Dam, M Steenhuis, EW Stalman, LYL Kummer, ... Lancet Rheumatol 4 (5), e338-e350, 2022 | 9 | 2022 |
| Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity KPJ Van Dam, AG Volkers, L Wieske, EW Stalman, LYL Kummer, ... BMC Infectious Diseases 23 (1), 332, 2023 | 8 | 2023 |
| Autonomic dysregulation, cognitive impairment, and symptoms of psychosis as an unusual presentation in an anti-aquaporin 4-positive patient AM Ruiter, JF Meilof, RRJ Somanje-Bolweg, E van Gorsel, NF Kalkers Case Reports in Neurology 9 (1), 12-16, 2017 | 8 | 2017 |
| Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases L Wieske, EW Stalman, PJK van Dam, LY Kummer, M Steenhuis, ... Annals of the Rheumatic Diseases 82 (6), 883-885, 2023 | 4 | 2023 |
| Efgartigimod in refractory autoimmune myasthenia gravis L Remijn‐Nelissen, MR Tannemaat, AM Ruiter, YJM Campman, ... Muscle & Nerve 70 (3), 325-332, 2024 | 3 | 2024 |
| mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8+ T cell responses J van den Dijssel, MC Duurland, VAL Konijn, LYL Kummer, RR Hagen, ... Journal of Autoimmunity 144, 103175, 2024 | 3 | 2024 |
| The face of myasthenia gravis AM Ruiter, WC Naber, JJGM Verschuuren, MR Tannemaat Neurology 95 (2), 89-90, 2020 | 1 | 2020 |